Impact of fish-oil consumption on the fatty acid content of plasma Nutritional, Metabolic, Endocrine Fish oil consumption
Conditions
Interventions
The five treatment groups are:
1. Control group (n = 42)
2. Capsules equivalent to 1 portion of oily fish per week (containing approximately 1.8 g eicosapentaenoic acid
Sponsors
MRC Human Nutrition Research (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Men and women, aged 20-80 years with a body mass index (BMI) in the range 18-35 kg/m2 will be recruited to the study.
Exclusion criteria
Exclusion criteria: 1. Known diagnosis of diabetes, cancer, cardiovascular disease or other chronic clinical conditions 2. Untreated hypertension 3. Concomitant prescription of anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDS), aspirin, steroids or immunosuppressants 4. Following a special diet, including vegetarians 5. Allergies or intolerance to fish 6. Consumption of oily fish more than once a month 7. Smokers 8. History of substance abuse or alcoholism 9. Pregnant, 2 kg in past 1 month) 11. Planning to change dietary habits, increase physical activity, change body weight, move away from the study centre locality or take a lengthy vacation during the time of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is plasma docosahexaenoic acid (DHA) status, expressed as a percentage of total plasma fatty acids. The three primary comparisons (on which sample size has been calculated) are: 1. Differences in plasma DHA status between treatment groups (2 portions versus control group) at 12 months 2. Differences in plasma DHA status between treatment groups (4 portions versus 2 portions group) at 12 months 3. Difference in plasma DHA status between age groups (old versus young) at 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 17/01/2019: Secondary comparisons will include gender effects, additional age comparisons and within-group time relationships (i.e. up to 12 months). Additionally, interactions between portions, age, time and gender will be explored. Secondary outcomes will include DHA status of other fatty acid pools (also expressed as a percentage of the total fatty acid profile); EPA status of fatty acid pools, EPA plus DHA status of fatty acid pools, other fatty acids, adipose tissue lipidome, and plasma markers of inflammation and physiological function including lipid mediators (i.e. oxylipins). Previous secondary outcome measures: Secondary comparisons will include gender effects, additional age comparisons and within-group time relationships. Additionally, interactions between portions, age, time and gender will be explored. Secondary outcomes will include DHA status of other fatty acid pools (also expressed as a percentage of the total fatty acid profile). | — |
Countries
United Kingdom
Outcome results
None listed